ProShare Advisors
PTX

ProShare Advisors’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

ProShare Advisors’s Portfolio PTX Stock Details PTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-5,071
Closed -$160K – 1733
2015
Q3 		$160K Buy
5,071
+1,229
+32% +$58.8K ﹤0.01% 1350
2015
Q2 		$227K Buy
3,842
+110
+3% +$7.76K ﹤0.01% 1448
2015
Q1 		$399K Buy
3,732
+482
+15% +$45.9K ﹤0.01% 1297
2014
Q4 		$305K Buy
3,250
+1,929
+146% +$184K ﹤0.01% 1503
2014
Q3 		$101K Sell
1,321
-300
-19% -$23.6K ﹤0.01% 2161
2014
Q2 		$146K Sell
1,621
-152
-9% -$9.31K ﹤0.01% 2274
2014
Q1 		$95K Buy
+1,773
New +$58.5K ﹤0.01% 2694
2013
Q4 		– Sell
-1,113
Closed -$30K – 2251
2013
Q3 		$30K Buy
+1,113
New +$35.8K ﹤0.01% 2519

Other funds holding PTX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

ProShare Advisors's PTX Position: Q4 2015 in Review

ProShare Advisors sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q4 2015, closing a stake of 5,071 shares — an estimated $160K sold.

ProShare Advisors first reported a position in PTX in Q3 2013 and held it in 8 quarters. The position peaked at $399K in Q1 2015. 101 funds tracked by Wall St. Rank hold PTX as of Q4 2015.

  • ProShare Advisors reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q4 2015 after selling out during the quarter.
  • ProShare Advisors sold 5,071 Pernix Therapeutics Holdings, Inc. shares in Q4 2015, an estimated $160K.
  • ProShare Advisors first reported a position in Pernix Therapeutics Holdings, Inc. in Q3 2013 and held it in 8 quarters.
  • ProShare Advisors's Pernix Therapeutics Holdings, Inc. position peaked at $399K in Q1 2015.
  • 101 funds tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q4 2015.

Based on ProShare Advisors's 13F filing for Q4 2015, filed 5 Feb 2016.